QUOTE AND NEWS
Jutia Group  Apr 14  Comment 
[Business Wire] - Merck , known as MSD outside the United States and Canada, and NewLink Genetics Corporation , confirmed today that the third, late-stage, clinical trial of their Ebola vaccine candidate rVSV-ZEBOV-GP has been initiated in Sierra...
Benzinga  Apr 14  Comment 
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and NewLink Genetics Corporation (NASDAQ: NLNK), confirmed today that the third, late-stage, clinical trial of their Ebola vaccine candidate rVSV-ZEBOV-GP (V920) has been...
Wall Street Journal  Apr 12  Comment 
NewLink Genetics has attracted big dollars for its cutting-edge work on cancer and Ebola treatments. But can a biotech in Iowa hang onto its Midwestern roots while still attracting top talent?
Benzinga  Apr 2  Comment 
Analysts at Jefferies downgraded NewLink Genetics Corporation (NASDAQ: NLNK) from Buy to Hold. The price target for NewLink Genetics is set to $50. NewLink Genetics shares have gained 115.93% over the past 52 weeks, while the S&P 500 index has...
TheStreet.com  Mar 2  Comment 
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet, Inc., or any of its contributors.  TheStreet Ratings quantitative algorithm evaluates over 4,300 stocks on...
TheStreet.com  Mar 2  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES Cracker Barrel was downgraded to hold from buy at Miller Tabak. This was a valuation call, based on a $150 12-month price target, Miller Tabak said. Crane was downgraded to underperform from buy at...
Jutia Group  Feb 19  Comment 
[GlobeNewswire] - AMES, Iowa -- NewLink Genetics Corporation today announced that it had received notification from Merck that the milestone event specified in the license and collaboration agreement between the two companies ... Read more on...
Benzinga  Dec 22  Comment 
NewLink Genetics Corp (NASDAQ: NLNK) and Merck & Co., Inc. (NYSE: MRK) on Monday announced a contract for development of an Ebola vaccine. According to the press release, the Biomedical Advanced Research and Development Authority (BARDA) of...




 
TOP CONTRIBUTORS

NewLink Genetics (NASDAQ:NLNK) is a biopharmaceutical which develops drugs to help treat cancer patients.[1] The company focuses on immunotherapy - or treatment by causing the immune system to either act or cease to act. In other words, NewLink Genetics attempts to encourage the patients immune system to combat the cancerous cells rather than attempting to kill the cells directly.[2] NewLink Genetics revenues are dependent on the discovery and FDA approval of its therapies.

Business Overview

For the full year 2010, NewLink generated $2.1M in grant revenue. This was an over 100% increase from the $.9M in 2009. Since the company spends heavily on research and development, it still reported a net loss for 2010 of $16.6M. This compares to a net loss of $10.2M in 2009. [3]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on November 10, 2011. The company offered 6.2M shares each for $7. The company had already planned to sell 5.5M shares. However, since they priced below the $10-$12 range, they increased shares. The deal raised a total of $43M. The lead mangers of the deal were Stifel Financial (SF) and Canaccord Genuity.[4]

Trends & Forces

Dependence on FDA approval

As of its IPO, NewLink did not have any FDA approved drugs. It's quite clear that without a completed drug, the company will be unable to produce substantial operating revenue. As a result, the company's performance is limited to actions from the FDA. Furthermore, since NewLink is in the process of developing new, untested treatments, there is no clear guidance for the likelihood of approval or the likelihood that physicians will adopt new treatments.[5]

  1. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Overview p. 1
  2. American Cancer Society - Find Support and Treatment "Immunotherapy"
  3. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Selected Financial Data p. 51
  4. Renaissance Capital - IPO Home "NewLink Genetics prices IPO at $7, below the range" 11 Nov 2011
  5. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Risk Factors" pp. 11-15
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki